Cyclacel Net Income vs Income Tax Expense Analysis
| CYCC Stock | USD 0.36 0.01 2.70% |
Cyclacel Pharmaceuticals financial indicator trend analysis is way more than just evaluating Cyclacel Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cyclacel Pharmaceuticals is a good investment. Please check the relationship between Cyclacel Pharmaceuticals Net Income and its Income Tax Expense accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.
Net Income vs Income Tax Expense
Net Income vs Income Tax Expense Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cyclacel Pharmaceuticals Net Income account and Income Tax Expense. At this time, the significance of the direction appears to have very week relationship.
The correlation between Cyclacel Pharmaceuticals' Net Income and Income Tax Expense is 0.22. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Income Tax Expense in the same time period over historical financial statements of Cyclacel Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Cyclacel Pharmaceuticals' Net Income and Income Tax Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Cyclacel Pharmaceuticals are associated (or correlated) with its Income Tax Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Tax Expense has no effect on the direction of Net Income i.e., Cyclacel Pharmaceuticals' Net Income and Income Tax Expense go up and down completely randomly.
Correlation Coefficient | 0.22 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Cyclacel Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Cyclacel Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Income Tax Expense
Most indicators from Cyclacel Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cyclacel Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.At present, Cyclacel Pharmaceuticals' Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.04, whereas Selling General Administrative is forecasted to decline to about 5.9 M.
| 2023 | 2024 (projected) | Discontinued Operations | 17.1K | 30.4K | Cost Of Revenue | 28.8K | 27.4K |
Cyclacel Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Cyclacel Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cyclacel Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 15.3M | 36.8M | 42.6M | 27.5M | 8.8M | 8.4M | |
| Total Stockholder Equity | 11.7M | 33.3M | 37.3M | 15.5M | 607K | 576.7K | |
| Retained Earnings | (357.6M) | (366.1M) | (385.0M) | (406.2M) | (428.3M) | (406.9M) | |
| Common Stock Shares Outstanding | 54.4K | 242.2K | 595.1K | 657.6K | 850.8K | 893.4K | |
| Liabilities And Stockholders Equity | 15.3M | 36.8M | 42.6M | 27.5M | 8.8M | 8.4M | |
| Other Stockholder Equity | 370.1M | 400.1M | 423.0M | 414.0M | 429.8M | 284.3M | |
| Total Liab | 3.6M | 3.5M | 5.3M | 12.0M | 8.2M | 14.1M | |
| Other Current Liab | 1.5M | 2.0M | 3.2M | 4.8M | 4.6M | 3.4M | |
| Total Current Liabilities | 2.4M | 2.5M | 5.3M | 7.4M | 8.2M | 5.8M | |
| Property Plant And Equipment Net | 1.3M | 1.3M | 94K | 174K | 102K | 96.9K | |
| Net Debt | (10.7M) | (32.3M) | (36.5M) | (18.2M) | (3.3M) | (3.5M) | |
| Accounts Payable | 890K | 514K | 2.1M | 2.6M | 3.5M | 2.2M | |
| Cash | 11.9M | 33.4M | 36.6M | 18.3M | 3.4M | 3.2M | |
| Non Current Assets Total | 1.3M | 1.3M | 1.6M | 3.1M | 1.4M | 1.7M | |
| Non Currrent Assets Other | (1.3M) | (1.3M) | 1.6M | 2.9M | 1.3M | 1.3M | |
| Cash And Short Term Investments | 11.9M | 33.4M | 36.6M | 18.3M | 3.4M | 3.2M | |
| Non Current Liabilities Total | 1.2M | 1.1M | 30K | 4.6M | 37K | 35.2K | |
| Other Current Assets | 103K | 750K | 4.4M | 6.1M | 4.1M | 4.3M | |
| Property Plant And Equipment Gross | 1.3M | 1.3M | 94K | 174K | 522K | 839.0K | |
| Total Current Assets | 14.0M | 35.5M | 40.9M | 24.4M | 7.4M | 7.1M | |
| Accumulated Other Comprehensive Income | (819K) | (746K) | (748K) | (1.3M) | (908K) | (953.4K) | |
| Common Stock | 17K | 6K | 10K | 4.5M | 1K | 950.0 | |
| Net Receivables | 1.3M | 1.3M | 3.7M | 5.6M | 2.9M | 2.7M | |
| Inventory | 703K | 684K | 577K | (5.6M) | (5.1M) | (4.8M) | |
| Property Plant Equipment | 27K | 106K | 94K | 174K | 156.6K | 148.8K | |
| Retained Earnings Total Equity | (342.5M) | (349.8M) | (357.6M) | (366.1M) | (329.5M) | (345.9M) | |
| Net Tangible Assets | 11.7M | 33.3M | 37.3M | 15.5M | 17.8M | 23.9M | |
| Capital Surpluse | 365.1M | 365.8M | 370.1M | 400.1M | 460.1M | 394.6M | |
| Non Current Liabilities Other | 124K | 100K | 1.2M | 1.1M | 1.2M | 1.3M | |
| Net Invested Capital | 11.7M | 33.3M | 37.3M | 20.0M | 607K | 576.7K | |
| Net Working Capital | 11.6M | 33.0M | 35.6M | 17.0M | (717K) | (681.2K) | |
| Capital Stock | 17K | 6K | 10K | 4.5M | 1K | 950.0 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cyclacel Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclacel Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclacel Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclacel Pharmaceuticals Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (27.40) | Revenue Per Share 0.044 | Quarterly Revenue Growth (0.99) | Return On Assets (1.03) | Return On Equity (5.71) |
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.